

Exhibit 10

GSK
Corporate IP

04 SEP 2001

Received NFSP

Heath House,
28, West Street,
Reigate,
Surrey,
RH2 9BX
31st Aug 2001

Dear Jill,

I received your letter today and have reacquainted myself with the US patent in question. I have no problems with Neil Pearson and myself being named as co-authors on this case. I'm sure that Neil has made an appropriate contribution to the invention.

I would like however to point out that I had many discussions both informal and during scheduled meetings, with a large number of chemists (including Neil) during my time at Beecham and SB. These discussions inevitably covered many structural changes which I thought would prove interesting and could lead to new and active series of molecules being discovered. I also briefed Neil (and members of the combinatorial chemistry group) very fully on all potential new structures which I had thought of in order to expand the scope of my invention when I handed over the management of the feasibility study to Neil on my departure from Harlow.

As I have said I was about to sign the appropriate declarations when I noticed that I am declaring all statements to be true and if this was knowingly breached then I am liable to be fined or imprisoned. I therefore have a problem with the statement that "**for a valuable consideration paid to me by SmithKline Beecham, the receipt of which is hereby acknowledged.....**" I have not received anything which I could interpret as covering this statement from SB. I do not think that it could be my salary as I was twice given grade 4 appraisal ratings during my time working on the Quinicines and told that my work was below standard. My salary suffered accordingly!!

I was also told to hide the fact that our lead for this series was derived from compounds supplied to us by Chemi Farma and still held by Beecham despite Chemi Farma being informed that all our samples had been destroyed after they were found to be of no interest in the cardiovascular screens.

You will also recall that I was completely ignored by the senior management within Medicinal Chemistry for 8 years despite my constant belief that this area would lead to an important drug candidate with massive potential sales (a billion \$ drug)!!

I therefore would like to hear what valuable consideration you intend to offer me to validate the statement which I will be signing.

I look forward to hearing from you in due course.

Yours sincerely,



Ian K Hatton (Dr)